Application of new acute kidney injury biomarkers in human randomized controlled trials

Kidney International

Volumn 89, Issue 6, 2016, Pages 1372-1379

  Parikh, Chirag R ^a,b   Moledina, Dennis G ^a   Coca, Steven G ^c   Thiessen Philbrook, Heather R ^a   Garg, Amit X ^d  

^a YALE UNIVERSITY   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

acute kidney injury; cardiovascular disease; proteomic analysis

Indexed keywords

BIOLOGICAL MARKER; CREATINE; INTERLEUKIN 18; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; CREATININE; LCN2 PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DETERMINATION; PROTEIN FUNCTION; RENAL PROTECTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; BLOOD; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COMPARATIVE STUDY; KIDNEY FUNCTION TEST; KIDNEY TUBULAR NECROSIS, ACUTE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ACUTE KIDNEY INJURY; BIOMARKERS; CARDIOPULMONARY BYPASS; CREATININE; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-18; KIDNEY FUNCTION TESTS; KIDNEY TUBULAR NECROSIS, ACUTE; LIPOCALIN-2; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 84978171029     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1016/j.kint.2016.02.027     Document Type: Article

References (35)

1. 1 Tong, A., Chando, S., Crowe, S., et al. Research priority setting in kidney disease: a systematic review. Am J Kidney Dis 65 (2015), 674–683.
2. 2 Molitoris, B.A., Urinary biomarkers: alone are they enough?. J Am Soc Nephrol 26 (2015), 1485–1488.
3. 3 Stevens, L.A., Coresh, J., Greene, T., et al. Assessing kidney function — measured and estimated glomerular filtration rate. N Engl J Med 354 (2006), 2473–2483.
4. 4 Coca SG, Zabetian A, Ferket BS, et al. Evaluation of short-term changes in serum creatinine level as a meaningful end point in randomized clinical trials [e-pub ahead of print]. J Am Soc Nephrol. http://dx.doi.org/10.1681/ASN.2015060642, accessed April 14, 2016.
5. 5 Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. Center for Drug Evaluation and Research, US Food and Drug Administration, Department of Health and Human Services; 2014.
6. 6 Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69 (2001), 89–95.
7. 7 Jun, M., Turin, T.C., Woodward, M., et al. Assessing the validity of surrogate outcomes for ESRD: a meta-analysis. J Am Soc Nephrol 26 (2015), 2289–2302.
8. 8 Bihorac, A., Chawla, L.S., Shaw, A.D., et al. Validation of cell-cycle arrest biomarkers for acute kidney injury using clinical adjudication. Am J Respir Crit Care Med 189 (2014), 932–939.
9. 9 Kashani, K., Al-Khafaji, A., Ardiles, T., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care, 17, 2013, R25.
10. 10 Waikar, S.S., Betensky, R.A., Emerson, S.C., et al. Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol 23 (2012), 13–21.
11. 11 Parikh, C.R., Jani, A., Melnikov, V.Y., et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43 (2004), 405–414.
12. 12 Belcher, J.M., Sanyal, A.J., Peixoto, A.J., et al. Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury. Hepatology 60 (2014), 622–632.
13. 13 Draft Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products. Center for Drug Evaluation and Research / Center for Biologics Evaluation and Research / Center for Devices and Radiological Health, US Food and Drug Administration; 2012.
14. 14 Fried, L.F., Duckworth, W., Zhang, J.H., et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 4 (2009), 361–368.
15. 15 Fried, L.F., Emanuele, N., Zhang, J.H., et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369 (2013), 1892–1903.
16. 16 de Zeeuw, D., Akizawa, T., Audhya, P., et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 369 (2013), 2492–2503.
17. 17 Torres, V.E., Abebe, K.Z., Chapman, A.B., et al. Angiotensin blockade in late autosomal dominant polycystic kidney disease. N Engl J Med 371 (2014), 2267–2276.
18. 18 Parikh, C.R., Devarajan, P., Zappitelli, M., et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after pediatric cardiac surgery. J Am Soc Nephrol 22 (2011), 1737–1747.
19. 19 Parikh, C.R., Coca, S.G., Thiessen-Philbrook, H., et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 22 (2011), 1748–1757.
20. 20 Mishra, J., Dent, C., Tarabishi, R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 (2005), 1231–1238.
21. 21 Roy A. Stifling new cures: the true cost of lengthy clinical drug trials. Project FDA report, Manhattan Institute For Policy Research, 2012.
22. 22 Piccart-Gebhart, M.J., Procter, M., Leyland-Jones, B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005), 1659–1672.
23. 23 Accurso, F.J., Rowe, S.M., Clancy, J.P., et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 363 (2010), 1991–2003.
24. 24 Atkins, R.C., Briganti, E.M., Lewis, J.B., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005), 281–287.
25. 25 de Zeeuw, D., Remuzzi, G., Parving, H.-H., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004), 2309–2320.
26. 26 Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium. Center for Drug Evaluation and Research, US Food and Drug Administration; 2009.
27. 27 Garg, A.X., Devereaux, P.J., Yusuf, S., et al. Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. JAMA 311 (2014), 2191–2198.
28. 28 Sharyo, S., Yokota-Ikeda, N., Mori, M., et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 74 (2008), 577–584.
29. 29 Gueler, F., Park, J.-K., Rong, S., et al. Statins attenuate ischemia-reperfusion injury by inducing heme oxygenase-1 in infiltrating macrophages. Am J Pathol 170 (2007), 1192–1199.
30. 30 Tabata, M., Khalpey, Z., Pirundini, P.A., et al. Renoprotective effect of preoperative statins in coronary artery bypass grafting. Am J Cardiol 100 (2007), 442–444.
31. 31 Molnar, A.O., Parikh, C.R., Coca, S.G., et al. Association between preoperative statin use and acute kidney injury biomarkers in cardiac surgical procedures. Ann Thorac Surg 97 (2014), 2081–2087.
32. 32 Parikh, C.R., Coca, S.G., Thiessen-Philbrook, H., et al. Post-operative biomarkers predict acute kidney injury and poor outcomes after cardiac surgery in adults. J Am Soc Nephrol 22 (2011), 1748–1757.
33. 33 Parikh, C.R., Thiessen-Philbrook, H., Garg, A.X., et al. Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol 8 (2013), 1079–1088.
34. 34 Levey, A.S., Stevens, L.A., Schmid, C.H., et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150 (2009), 604–612.
35. 35 Mehta, R.L., Kellum, J.A., Shah, S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care, 11, 2007, R31.